James E. Bradner
Impact in
- Hematology top 0.05%
- Multiple Myeloma Research and Treatments
- Molecular Biology top 0.05%
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
- Histone Deacetylase Inhibitors Research
- Epigenetics and DNA Methylation
- Genomics and Chromatin Dynamics
- RNA Research and Splicing
Papers in
-
- Protein Degradation and Inhibitors 140
- Histone Deacetylase Inhibitors Research 64
- Ubiquitin and proteasome pathways 60
- Genomics and Chromatin Dynamics 24
- Epigenetics and DNA Methylation 18
- Hematology 57
- Multiple Myeloma Research and Treatments 43
- Acute Myeloid Leukemia Research 16
- Co-authors
- Richard A. Young (14 shared papers)Jun Qi (53 shared papers)Dennis L. Buckley (18 shared papers)Denes Hnisz (5 shared papers)Joshiawa Paulk (13 shared papers)Georg E. Winter (12 shared papers)Justin M. Roberts (14 shared papers)Ralph Mazitschek (17 shared papers)
- Journals
- Blood (32 papers)Cancer Research (16 papers)Proceedings of the National Academy of Sciences (8 papers)Cell (8 papers)Nature Chemical Biology (7 papers)
- Partner nations
- United StatesChinaUnited Kingdom
In The Last Decade
James E. Bradner
212 papers receiving 28.9k citations
James E. Bradner's Hit Papers
Peers
Comparison fields: 5 of 157
- Hematology 5.4k
- Molecular Biology 23.5k
- Oncology 5.8k
- Cancer Research 2.1k
- Genetics 1.2k
Countries citing papers authored by James E. Bradner
This map shows the geographic impact of James E. Bradner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Bradner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Bradner more than expected).
Fields of papers citing papers by James E. Bradner
This network shows the impact of papers produced by James E. Bradner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Bradner. The network helps show where James E. Bradner may publish in the future.
Co-authors
The 25 scholars most cited alongside James E. Bradner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 218 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Hit paper breakdown → | 2011 | 1447 |
| 2 | Phthalimide conjugation as a strategy for in vivo target protein degradation Hit paper breakdown → | 2015 | 1281 |
| 3 | HDAC2 negatively regulates memory formation and synaptic plasticity Hit paper breakdown → | 2009 | 1280 |
| 4 | The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins Hit paper breakdown → | 2013 | 1132 |
| 5 | Transcriptional Amplification in Tumor Cells with Elevated c-Myc Hit paper breakdown → | 2012 | 1130 |
| 6 | Transcriptional Addiction in Cancer Hit paper breakdown → | 2017 | 774 |
| 7 | Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies Hit paper breakdown → | 2007 | 705 |
| 8 | YY1 Is a Structural Regulator of Enhancer-Promoter Loops Hit paper breakdown → | 2017 | 689 |
| 9 | The dTAG system for immediate and target-specific protein degradation Hit paper breakdown → | 2018 | 682 |
| 10 | Direct inhibition of the NOTCH transcription factor complex Hit paper breakdown → | 2009 | 621 |
| 11 | PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib Hit paper breakdown → | 2007 | 604 |
| 12 | Chemical phylogenetics of histone deacetylases Hit paper breakdown → | 2010 | 584 |
| 13 | Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma Hit paper breakdown → | 2013 | 560 |
| 14 | 2005 | 475 | |
| 15 | Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition Hit paper breakdown → | 2013 | 465 |
| 16 | 2014 | 464 | |
| 17 | Plasticity in binding confers selectivity in ligand-induced protein degradation Hit paper breakdown → | 2018 | 446 |
| 18 | Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation Hit paper breakdown → | 2017 | 412 |
| 19 | 2015 | 362 | |
| 20 | 2015 | 355 |
About James E. Bradner
James E. Bradner is a scholar working on Molecular Biology, Hematology, Oncology, Organic Chemistry and Immunology, having authored 218 papers that have together received 29.3k indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (140 papers), Histone Deacetylase Inhibitors Research (64 papers), Ubiquitin and proteasome pathways (60 papers), Multiple Myeloma Research and Treatments (43 papers), Genomics and Chromatin Dynamics (24 papers), Peptidase Inhibition and Analysis (20 papers), Epigenetics and DNA Methylation (18 papers) and Acute Myeloid Leukemia Research (16 papers). The work is most often cited by research in Hematology (5.4k citations), Molecular Biology (23.5k citations), Oncology (5.8k citations), Cancer Research (2.1k citations) and Genetics (1.2k citations). James E. Bradner has collaborated with scholars based in United States, China and United Kingdom. Frequent co-authors include Richard A. Young, Jun Qi, Dennis L. Buckley, Denes Hnisz, Joshiawa Paulk, Georg E. Winter, Justin M. Roberts, Ralph Mazitschek, Charles Y. Lin and Tong Ihn Lee. Their work appears in journals such as Blood, Cancer Research, Proceedings of the National Academy of Sciences, Cell and Nature Chemical Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.